Microcatheter Market Size to Reach USD 1.79 Billion by 2035 | SNS Insider

The global microcatheter market is valued at USD 1.05 billion in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by increasing adoption of minimally invasive cardiovascular and neurovascular procedures, rising prevalence of cardiovascular and neurovascular disorders, and advancements in catheter technologies. Aspiration microcatheters lead with 36% market share, while steerable microcatheters are the fastest-growing segment. North America dominates with 34% of global revenues, with Asia-Pacific emerging as the fastest-growing region.

06/19/2026, 5:09 AM • GlobeNewswire

Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months

Boston Scientific shares have plummeted over 50% year-to-date due to repeated downward guidance revisions, particularly regarding declining Watchman procedure usage. Despite bearish market sentiment, 27 of 31 analysts maintain buy ratings with a consensus price target of $78 (65% upside), though the article cautions this recovery may be challenging without faster-than-expected growth acceleration.

06/13/2026, 12:15 AM • The Motley Fool

Peripheral Vascular Devices Market by Type, End User - Global Forecast to 2031

The global peripheral vascular devices market is projected to grow from USD 10.02 billion in 2026 to USD 13.22 billion by 2031 at a CAGR of 5.7%, driven by rising prevalence of vascular disorders, aging populations, and innovations in minimally invasive devices. Asia Pacific is expected to see the highest growth, with major players including Boston Scientific, Medtronic, and Abbott leading the market.

06/02/2026, 4:49 AM • GlobeNewswire

Zscaler, AutoZone, And Regencell Are Among Top 10 Large-Cap Losers Last Week (May 25-May 29): Are The Others In Your Portfolio?

Ten large-cap stocks experienced significant declines during the week of May 25-29, 2026. Zscaler led losses with a 20.06% drop following disappointing Q3 results and weak Q4 guidance. Other major losers included Boston Scientific (16.95%), AutoZone (14.21%), Regencell Bioscience (12.61%), and Venture Global (10.87%). Declines were attributed to earnings misses, analyst downgrades, and energy sector weakness following geopolitical developments.

05/31/2026, 9:49 AM • Benzinga

Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention

Boston Scientific announced a $1.5 billion investment for a 34% stake in MiRus LLC, gaining entry into the transcatheter aortic valve replacement (TAVR) market projected to grow from $4.5 billion in 2024 to $12.2 billion by 2033. The deal includes an option to acquire the remaining stake for up to $3 billion if milestones are met. Wall Street remains bullish with 92% of analysts rating the stock a buy, while insider buying and a $2 billion share buyback signal management confidence.

05/27/2026, 2:15 PM • The Motley Fool

Dow Jones Hit Records Above 50,600 As Oil Sinks Below $90: Stock Market Today

The Dow Jones Industrial Average reached a record high above 50,600 while the Nasdaq 100 declined 0.7% on Wednesday. Oil prices fell sharply below $90 per barrel following reports of potential Iran negotiations, benefiting travel and leisure stocks. The S&P 500 edged slightly lower as semiconductor stocks retreated, while consumer discretionary and hospitality sectors led gains.

05/27/2026, 1:29 PM • Benzinga

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter, meeting both primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The trial of 420 patients achieved a 93.3% safety rate and 93.7% procedural success rate, exceeding pre-specified benchmarks. The device uses laser-generated acoustic pressure waves to fracture calcium buildup in coronary arteries before stent implantation.

05/19/2026, 12:01 PM • Benzinga

Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal

Boston Scientific invested $1.5 billion in MiRus to acquire a 34% equity stake and exclusive option to acquire the SIEGEL Balloon Expandable TAVR system for treating severe aortic stenosis. The investigational device features a smaller delivery profile and advanced materials. Boston Scientific shares surged 5.56% on the announcement, though the stock remains down 42% year-to-date.

05/18/2026, 2:40 PM • Benzinga

BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSX

Rosen Law Firm announces securities class action lawsuits against Boston Scientific Corporation, Camping World Holdings, Inc., and ADMA Biologics, Inc. The Boston Scientific lawsuit alleges the company made false statements about its U.S. Electrophysiology segment's sustainability while concealing material adverse facts, leading to a net income miss and underwhelming guidance. Investors who purchased shares during specified class periods are encouraged to join the litigation before upcoming deadlines.

05/03/2026, 6:00 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Boston Scientific Corporation alleging that the company made materially false and misleading statements regarding its U.S. electrophysiology segment's growth sustainability. The complaint claims management failed to disclose material adverse trends in procedure volumes, competitive pressures, and regulatory headwinds that negatively impacted the segment. Investors who purchased BSX securities between July 23, 2025, and February 3, 2026, are eligible to join the case.

05/03/2026, 12:00 PM • GlobeNewswire

BSX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSX

A securities class action lawsuit has been filed against Boston Scientific Corporation for allegedly making false and misleading statements about its U.S. Electrophysiology segment during July 23, 2025 to February 3, 2026. The lawsuit claims management concealed that the segment's growth was unsustainable and approaching an earlier decline than anticipated, leading to a net income miss and underwhelming guidance. Investors have until May 4, 2026 to serve as lead plaintiff.

04/29/2026, 6:43 PM • GlobeNewswire

Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investors

Boston Scientific faces a class action lawsuit after its stock fell 17% on February 4, 2026, following the disclosure that fourth quarter GAAP net income of $0.45 per share missed its guidance range of $0.48-$0.52. The lawsuit alleges the company misled investors about its growth projections and failed to disclose competitive pressures from new entrants in the U.S. Electrophysiology market that undermined its ability to maintain 2x market growth.

04/28/2026, 9:00 AM • GlobeNewswire

BSX DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSX

A securities class action lawsuit has been filed against Boston Scientific Corporation for allegedly making false and misleading statements about its U.S. Electrophysiology segment during July 23, 2025 to February 3, 2026. The lawsuit claims management concealed that the segment's growth was unsustainable and approaching an earlier decline than anticipated, leading to a net income miss and underwhelming guidance. Investors have until May 4, 2026 to serve as lead plaintiff.

04/26/2026, 9:49 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Boston Scientific Corporation alleging that the company made materially false and misleading statements regarding its U.S. electrophysiology segment's growth sustainability. The complaint claims management failed to disclose material adverse trends in procedure volumes, competitive pressures, and regulatory headwinds. Investors who purchased BSX securities between July 23, 2025, and February 3, 2026, may be eligible to join the case.

04/26/2026, 12:00 PM • GlobeNewswire

BSX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSX

A securities class action lawsuit has been filed against Boston Scientific Corporation for allegedly making false and misleading statements about its U.S. Electrophysiology segment. The lawsuit claims defendants concealed that the segment's growth was unsustainable and approaching a tipping point earlier than anticipated, leading to a net income miss and underwhelming guidance. Investors who purchased BSX stock between July 23, 2025 and February 3, 2026 may be eligible for compensation. The lead plaintiff deadline is May 4, 2026.

04/22/2026, 10:42 PM • GlobeNewswire